KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Long-Term Investments (2017 - 2025)

Nektar Therapeutics (NKTR) has 13 years of Long-Term Investments data on record, last reported at $7.8 million in Q1 2025.

  • For Q1 2025, Long-Term Investments fell 78.91% year-over-year to $7.8 million; the TTM value through Mar 2025 reached $7.8 million, down 78.91%, while the annual FY2024 figure was $13.9 million, 46.3% down from the prior year.
  • Long-Term Investments reached $7.8 million in Q1 2025 per NKTR's latest filing, down from $13.9 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $96.1 million in Q1 2021 and bottomed at $4.5 million in Q3 2024.
  • Average Long-Term Investments over 5 years is $33.9 million, with a median of $30.0 million recorded in 2021.
  • Peak YoY movement for Long-Term Investments: plummeted 84.45% in 2022, then plummeted 46.3% in 2024.
  • A 5-year view of Long-Term Investments shows it stood at $64.8 million in 2021, then plummeted by 86.23% to $8.9 million in 2022, then surged by 189.26% to $25.8 million in 2023, then tumbled by 46.3% to $13.9 million in 2024, then crashed by 44.07% to $7.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Long-Term Investments were $7.8 million in Q1 2025, $13.9 million in Q4 2024, and $4.5 million in Q3 2024.